id stringlengths 40 40 | source stringclasses 9
values | title stringlengths 2 345 | clean_text stringlengths 35 1.63M | raw_text stringlengths 4 1.63M | url stringlengths 4 498 | overview stringlengths 0 10k |
|---|---|---|---|---|---|---|
7a73f9287841533eeb11c025026322a23d519f2c | cco | None | # QUESTIONS Diagnosis/Staging
What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of head and neck cancer? What benefit to clinical management does PET or PET/CT contribute to the assessment of tr... | # QUESTIONS Diagnosis/Staging
What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of head and neck cancer? What benefit to clinical management does PET or PET/CT contribute to the assessment of tr... | None | None |
0ca6b1adf1e6c001dc70cd13be35a1e8a4c14839 | cco | None | # GUIDELINE OBJECTIVES
To update clinical guidance on the use of multigene profiling assays in individuals with earlystage invasive breast cancer.
# TARGET POPULATION
Individuals diagnosed with early-stage invasive breast cancer for whom further information is needed for prognosis and treatment decision making. In thi... | This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or ... | None | None |
68984194848f42b555d2a3c9077ac7a1e53f976b | cco | None | # GUIDELINE OBJECTIVES
To make recommendations with respect to the use of T2-weighted magnetic resonance imaging (MRI) ± functional sequences in the pre-treatment local staging of patients with newly diagnosed prostate cancer.
- MRI refers to T2-weighted MRI.
- Functional sequences include dynamic contrast-enhanced ima... | This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization. Disclaimer Care has been... | None | None |
c80ad0d5ba1eee75e1702847d361abd6ce4bc7b0 | cco | None | Evidence-Based Series 4-5 is CURRENT as of November 2022. In June 2016 a literature search and review determined that the recommendations were still valid and not causing harm but all relevant aspects of the topic were not covered by the original guideline. This document was identified for an UPDATE but it is anticipat... | Evidence-Based Series 4-5 is CURRENT as of November 2022. In June 2016 a literature search and review determined that the recommendations were still valid and not causing harm but all relevant aspects of the topic were not covered by the original guideline. This document was identified for an UPDATE but it is anticipat... | None | None |
7a09ab0610ecc9990db3362ca0b00a37a016acb4 | cco | None | # GUIDELINE OBJECTIVES
To make recommendations with respect to the role of adjuvant systemic chemotherapy in stage II and III colon cancer patients who have undergone complete resection with curative intent.
# TARGET POPULATION
The target population consists of adult patients with stage II and III colon cancer who hav... | # GUIDELINE OBJECTIVES
To make recommendations with respect to the role of adjuvant systemic chemotherapy in stage II and III colon cancer patients who have undergone complete resection with curative intent.
# TARGET POPULATION
The target population consists of adult patients with stage II and III colon cancer who hav... | None | None |
8dc99ba0e643ca9733145769790691870c07fb3b | cco | None | # Section 1:
Recommendations Section 2:
Recommendations and Key Evidence Section 3: Guideline Methods Overview Section 4: Systematic Review Section 5:
Internal and External Review
For information about this document, please contact Alex Sun, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905... | # Section 1:
Recommendations Section 2:
Recommendations and Key Evidence Section 3: Guideline Methods Overview Section 4: Systematic Review Section 5:
Internal and External Review
For information about this document, please contact Alex Sun, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905... | None | None |
3fc88a47cdb08da328a10eddd380c8ffc6415303 | cco | None | These guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making.# GUIDELINE OBJECTIVE
How should patients presenting to family physicians and other primary care providers (PCPs) with signs and/or symptoms of prostate cancer, including incidenta... | These guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making.# GUIDELINE OBJECTIVE
How should patients presenting to family physicians and other primary care providers (PCPs) with signs and/or symptoms of prostate cancer, including incidenta... | None | None |
5b1aedafa44e59813f737012f097d77bc96dd71b | cco | None | To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence.An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) wit... | To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence.An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) wit... | None | None |
2f0b7d32a0fed28287602ada73d594179dd16882 | cco | None | In Canada in 2010, an estimated 2600 new cases of ovarian cancer will be diagnosed and, of those cases, 1750 women will die, making ovarian cancer the seventh most prevalent form of cancer in Canadian women and their fifth leading cause of cancer death (1). Women with ovarian cancer typically have subtle, non-specific ... | A
# INTRODUCTION
In Canada in 2010, an estimated 2600 new cases of ovarian cancer will be diagnosed and, of those cases, 1750 women will die, making ovarian cancer the seventh most prevalent form of cancer in Canadian women and their fifth leading cause of cancer death (1). Women with ovarian cancer typically have sub... | None | None |
43f3fad5ab04c54218779ea3e2a205987f8f58e1 | cco | None | To determine the risk of cutaneous malignant melanoma (herein referred to as melanoma) associated with use of indoor tanning devices, including impact of age at first use and frequency of use on the relative risk of developing melanoma.
# TARGET POPULATION
All users of indoor tanning beds are the target population of ... | An assessment conducted in November 2022 deferred the review of Evidencebased Series (EBS) 8-8. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol).# GUIDELINE OBJECT... | None | None |
b250c4a022911b4bcf8e58ffe0b039aa580f9931 | cco | None | # RECOMMENDATIONS, KEY EVIDENCE, AND JUSTIFICATION
RECOMMENDATION 1 DNMT3A mutation testing should be included as a biomarker test in cytogenetically normal AML patients.
# Summary of Key Evidence for Recommendation
Four (8,10,13,15) of the eight studies (8)(9)(10)(11)(12)(13)(14)(15) included in the systematic review... | # RECOMMENDATIONS, KEY EVIDENCE, AND JUSTIFICATION
RECOMMENDATION 1 DNMT3A mutation testing should be included as a biomarker test in cytogenetically normal AML patients.
# Summary of Key Evidence for Recommendation
Four (8,10,13,15) of the eight studies (8)(9)(10)(11)(12)(13)(14)(15) included in the systematic review... | None | None |
6b2a60ca471b09eb9492fd946c4ac35e74b5b717 | cco | None | # TARGET POPULATION
All adult MM patients considered for treatment that includes blood or marrow transplantation.
# RECOMMENDATIONS AND SUPPORTING EVIDENCE
Autologous SCT is the recommended treatment option for patients with newly diagnosed MM, as part of the initial treatment plan.
# Supporting evidence
Evidence inc... | # TARGET POPULATION
All adult MM patients considered for treatment that includes blood or marrow transplantation.
# RECOMMENDATIONS AND SUPPORTING EVIDENCE
Autologous SCT is the recommended treatment option for patients with newly diagnosed MM, as part of the initial treatment plan.
# Supporting evidence
Evidence inc... | None | None |
4f223ab5b4cea812a4f4320ab695245e0741a229 | cco | None | # GUIDELINE OBJECTIVES
# INTENDED USERS
This guideline is intended for provincial policy makers, primary care physicians, nurse practitioners, radiologists, respirologists, thoracic surgeons, thoracic oncologists, and any health professionals involved with patients who may be at risk for developing lung cancer.
# REC... | #
Lung cancer is the most common cause of cancer death in Ontario. Contributing to the high mortality rate is a lack of an effective evidence-based screening method. Utilizing the two tests commonly used to screen for lung cancer, chest radiography (CXR) and sputum cytology, has not demonstrated a reduction in mortali... | None | None |
d9499ab9e25d048bd6e9a2a68a15b4aa59db8ee0 | cco | None | # INTENDED PURPOSE
- This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. - This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imagin... | # INTENDED PURPOSE
• This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. • This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imagin... | None | None |
11cd569b02196a7ab19210a3c06501587a6bb163 | cco | None | For further information about this report, please contact the authors through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca
For information about the PEBC and the most current version of all reports, please visit the CCO Web site at / or contact the PEBC office at: Phone: 905... | An assessment conducted in January 2023 deferred the review of Evidence-based Series (EBS) 17-8. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol) EBS 17-8 is compr... | None | None |
3d3b6b164e90596e73ac2873298acbcf4f64a111 | cco | None | - Does the addition of chemotherapy (CT) to radiotherapy (RT) improve outcome for patients with squamous cell cancer of the anal canal? 2. What are the optimal CT drugs for the treatment of patients with squamous cell cancer of the anal canal? 3. Does the use of induction CT before concurrent CT and RT improve outcome ... | An assessment conducted in December 2022 deferred the review of Evidence-based Series (EBS) 2-8 Version 2. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol) EBS 2-8... | None | None |
0ee4f9b150e2ee25bf2c3e2c65eef16adf490054 | cco | None | # Section 1: Recommendations
# RECOMMENDATIONS Recommendation 1: General Measures Committee Responsible for Policy and Procedures for Hazardous Drugs
It is strongly recommended that all institutions administering hazardous drugs form such a committee. It is also strongly recommended that this committee include, but no... | This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or ... | None | None |
2c855194bfd97aeca9af688924f1d86ab80b1f75 | cco | None | # INTENDED PURPOSE
- This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imaging... | # INTENDED PURPOSE
This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imagin... | None | None |
951a7fa7bae478229637320c7b3d6ddfad215acb | cco | None | New data and old data integrated in new Full Report Updated web publication.
# Not Applicable
# Table of Contents
# INTENDED USERS
This guideline is targeted for clinicians involved in the delivery of systemic treatment for cancer patients.
# RECOMMENDATIONS AND KEY EVIDENCE Recommendation 1a
First-line therapy w... | #
New data and old data integrated in new Full Report Updated web publication.
# Not Applicable
# Table of Contents
# INTENDED USERS
This guideline is targeted for clinicians involved in the delivery of systemic treatment for cancer patients.
# RECOMMENDATIONS AND KEY EVIDENCE Recommendation 1a
First-line therap... | None | None |
41c94c3f9e3a0766f9dcfb06ee079b475c217f92 | cco | None | # Cancer Care Ontario Sequence Variants in Hereditary Cancers
Guideline: An Endorsement of the 2015 Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
# Section 1: Gu... | Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinic... | None | None |
bf6e1eb522a4eab7be7fe352db156d156c5caa04 | cco | None | # INTENDED PURPOSE
- This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. - This recommendation report may also be useful to inform clinical decision making regarding the appropriate role of PET imaging a... | #
What benefit to clinical management does PET or PET/CT contribute when recurrence of esophageal cancer is suspected but not proven? What benefit to clinical management does PET or PET/CT contribute to restaging at the time of documented recurrence for esophageal cancer? What is the role of PET when a solitary metast... | None | None |
3d87ae87006f0ff0d02d47b78c08164b456228e5 | cco | None | # GUIDELINE OBJECTIVES
To update the 2015 guideline of the Program in Evidence-Based Care (PEBC) Ontario Health (Cancer Care Ontario) to provide guidance for managing surveillance of patients with stage I, II, III, or resectable IV melanoma who are clinically disease-free after treatment with curative intent (following... | This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or ... | None | None |
83a0ef38d11edb694a86312a5a0f539396042e66 | cco | None | Evidence-based Series 4-9 Version 2 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Follow-up after Primary Therapy for Endometrial Cancer Members of the Gynecology Cancer Disease Site Group An assessment conducted in November 2022 deferred the review of Evidence-Based Serie... | Evidence-based Series 4-9 Version 2 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Follow-up after Primary Therapy for Endometrial Cancer Members of the Gynecology Cancer Disease Site Group An assessment conducted in November 2022 deferred the review of Evidence-Based Serie... | None | None |
5307e95fdc2d3f5f8c1d826dacd25771d2fbc51e | cco | None | Questions 1. Should primary care providers routinely perform total-body skin examination on members of the general population to screen for melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin? 2. Should primary care providers routinely counsel members of the general population to perform skin self-e... | #
Questions 1. Should primary care providers routinely perform total-body skin examination on members of the general population to screen for melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin? 2. Should primary care providers routinely counsel members of the general population to perform skin sel... | None | None |
241c41c2bfa1135b8f27b65ee979fcd375ceb1d4 | cco | None | Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms: they include epithelial neuroendocrine carcinomas originating in multiple sites throughout the body as well as tumours of modified neurons arising in sympathetic or parasympathetic ganglia and the adrenal medulla (1,2). The latter express tyro... | This
# INTRODUCTION
Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms: they include epithelial neuroendocrine carcinomas originating in multiple sites throughout the body as well as tumours of modified neurons arising in sympathetic or parasympathetic ganglia and the adrenal medulla (1,2). Th... | None | None |
cc55bc1f02ab6adf2c07db61fbd9a22560939fa1 | cco | None | Given the potential toxicities associated with alemtuzumab, and given the limited nature of the clinical trials testing its use in broad populations of patients with CLL, the use of alemtuzumab in patients with important co-morbidities may be associated with excessive risks. Currently, there are no published randomized... | Given the potential toxicities associated with alemtuzumab, and given the limited nature of the clinical trials testing its use in broad populations of patients with CLL, the use of alemtuzumab in patients with important co-morbidities may be associated with excessive risks. Currently, there are no published randomi... | None | None |
b698253c2071f1ecb719b6f948c5c21e4d94a190 | cco | None | # QUESTIONS Overall Question
In patients presenting to primary care services with signs and/or symptoms of lung cancer, what should the referral process include?
The following questions are the factors considered in answering the overall question:
# TARGET POPULATION
Patients presenting in primary care settings compr... | # Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers: Guideline Recommendations
The 2011 recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Assessment and Review for a summary of... | None | None |
5c9b601991ece1e84103c5070a573dd41bb53a61 | cco | None | Although the incidence and mortality of gastric cancer has been steadily decreasing in Canadian men and women, this disease remains a global health problem, accounting for 10% of all new cancer cases and 12% of all cancer deaths worldwide (1). In Canada, the annual percent change in age-standardized incidence between 1... | The
# INTRODUCTION
Although the incidence and mortality of gastric cancer has been steadily decreasing in Canadian men and women, this disease remains a global health problem, accounting for 10% of all new cancer cases and 12% of all cancer deaths worldwide (1). In Canada, the annual percent change in age-standardized... | None | None |
7f3f6dc41c569927d37018a6d8d5350889ac831f | cco | None | To improve the quality and consistency of the management of depression for patients with cancer in Ontario.Adult patients with cancer who are diagnosed with a major depressive disorder based on a structured diagnostic interview, or who have a suspected depressive disorder based on meeting a threshold on a validated dep... | To improve the quality and consistency of the management of depression for patients with cancer in Ontario.Adult patients with cancer who are diagnosed with a major depressive disorder based on a structured diagnostic interview, or who have a suspected depressive disorder based on meeting a threshold on a validated dep... | None | None |
0344bcf6da381ed8b046d268476e2e80fa49d4a5 | cco | None | # GUIDELINE OBJECTIVES
The primary objective of this guideline is to develop recommendations related to the frequency by which prostate-specific antigen (PSA) levels should be tested in men after curative-intent treatment for prostate cancer and to define the most appropriate diagnostic testing if biochemical (BC) recu... | # Guideline 26-4: Section 1
# Follow-up Care and Psychosocial Needs of Survivors of Prostate Cancer: Recommendations Summary
Note To Users Of This Summary This Recommendations Summary may be useful as a quick reference to this guideline. Users are advised to consult the Complete Guideline Report for more information a... | None | None |
afe7ad2c3d196197b31ff182f3a12073a2a1c934 | cco | None | What benefit to clinical management does 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) contribute to the initial diagnosis or staging of lymphoma?What benefit to clinical management does FDG PET/CT contribute after conventional imaging is performed, in patients with suspected o... | What benefit to clinical management does 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) contribute to the initial diagnosis or staging of lymphoma?What benefit to clinical management does FDG PET/CT contribute after conventional imaging is performed, in patients with suspected o... | None | None |
392e56d54ce2a5a1e08100df71486f9aafb188d5 | cco | None | There are various definitions for palliative care, but most people would agree that "it focuses on care that addresses both physical and non-physical symptoms. It can be delivered throughout the course of the disease. It involves a team of healthcare providers and supports patients as well as their families." This evi... | This
# INTRODUCTION
There are various definitions for palliative care, but most people would agree that "it focuses on care that addresses both physical and non-physical symptoms. It can be delivered throughout the course of the disease. It involves a team of healthcare providers and supports patients as well as their... | None | None |
745dd61eb05abaf28da5239c7d5c77a13d1cb8ed | cco | None | # GUIDELINE OBJECTIVES
The objective of this guideline is to update a previous guideline on chemotherapy options for women with recurrent, metastatic, or persistent cervical cancer. The primary outcomes of interest are overall survival rate and quality of life. Other outcomes of interest include response rate, progress... | November 2020 placed Evidence-based Series (EBS) 4-20 Version 2 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each do... | None | None |
fdfed17344a33fa4464ed468835e72c47daafd65 | cco | None | What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of melanoma? What benefit to clinical management does PET or PET/CT contribute to the assessment of treatment response for melanoma? What bene... | # QUESTIONS
What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of melanoma? What benefit to clinical management does PET or PET/CT contribute to the assessment of treatment response for melan... | None | None |
b5fa1369af7db2058839f4086fe7e7829dabcd11 | cco | None | Peer review publication.
# TARGET POPULATION
- Patients of any age diagnosed with localized Ewing's sarcoma of bone who have completed neoadjuvant chemotherapy for the first objective - Patients of any age diagnosed with localized Ewing's sarcoma of bone who will undergo surgical management following neoadjuvant chemo... | This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.Care has been taken in th... | None | None |
0e738700904901102a9b807c7e6d67d00e5880b7 | cco | None | These recommendations apply to adult patients (≥18 years old) with unresectable metastatic colorectal cancer. The cytotoxic agents covered in this guideline include initial fluoropyrimidine (5-FU or capecitabine) either alone or in combination, irinotecan and oxaliplatin.
# INTENDED USERS
This guideline is intended fo... | An assessment conducted in December 2022 deferred the review of Evidencebased Series (EBS) 2-5. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol) Evidence-Based Ser... | None | None |
be2ea4dacc2da384edfe68c69a12645e73c601bc | cco | None | # Acute Myeloid Leukemia (AML)
What is the role of SCT in the treatment of AML?
# TARGET POPULATION
All adult patients with MDS or AML being considered for treatment that includes either blood or bone marrow transplantation.
# RECOMMENDATIONS AND SUPPORTING EVIDENCE MYELODYSPLASTIC SYNDROME (MDS)
Allogeneic transplan... | # Acute Myeloid Leukemia (AML)
What is the role of SCT in the treatment of AML?
# TARGET POPULATION
All adult patients with MDS or AML being considered for treatment that includes either blood or bone marrow transplantation.
# RECOMMENDATIONS AND SUPPORTING EVIDENCE MYELODYSPLASTIC SYNDROME (MDS)
Allogeneic transplan... | None | None |
4f2e3436434fd84bbd4dcfe76d2b8a92a791a450 | cco | None | # GUIDELINE OBJECTIVES
The objective of this guideline is to determine the most effective therapy for patients with thymic epithelial tumours.
# TARGET POPULATION
The target population are adult patients with thymic epithelial tumours, including thymoma, thymic carcinoma, and thymic neuroendocrine tumours (NETs).
# I... | This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or ... | None | None |
b3f1c73372c37477df2bf2f3844342b222452a82 | cco | None | Is there a role for high dose rate endobronchial brachytherapy (HDREB) in the palliation of respiratory symptoms in patients with non-small cell lung cancer? 2.
If so, what is the optimal dose of HDREB in this setting?
# Target Population
The recommendations apply to adult patients with symptomatic endobronchial disea... | #
Is there a role for high dose rate endobronchial brachytherapy (HDREB) in the palliation of respiratory symptoms in patients with non-small cell lung cancer? 2.
If so, what is the optimal dose of HDREB in this setting?
# Target Population
The recommendations apply to adult patients with symptomatic endobronchial di... | None | None |
6c1b8544bd4fd9f87723d5e8501fc79094398e98 | cco | None | # GUIDELINE OBJECTIVES
To make recommendations regarding the use of adjuvant systemic therapy in adult patients with completely resected cutaneous or mucosal melanoma with a high risk of recurrence.
# TARGET POPULATION
Adult patients with cutaneous or mucosal melanoma with high risk of recurrence who are rendered dise... | Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinic... | None | None |
686cf69c5d6eb035217f20723bb5a41c945d9dc7 | cco | None | # Questions Considered
Does treatment with imatinib mesylate (Gleevec TM have palliative benefit, in terms of tumour response, disease progression, survival or quality of life, for patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT tyrosine kinase receptor (identified by... | The diagnostic criteria for GIST have evolved in recent years. Specifically the discovery of the immunohistochemical marker for DOG 1 has led to its inclusion in the pathological work up of suspected GISTs. DOG-1 may also be expressed in GISTs that are c-kit negative (1-3) c-kit negative GISTs have been demonstrate... | None | None |
9d58acce0cecf01b70c88fa2d90f7e157620e190 | cco | None | The 2012 recommendations have been ENDORSED. This means that the recommendations are still current and relevant for decision making. Please see Section 3: Document Assessment and Review for a summary of updated evidence published between 2010 and 2019, and for details on how this Recommendation Report was ENDORSED.
# ... | An assessment conducted in February 2023 deferred the review of Recommendation Report SCT-2 Version 2. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol) Recommendat... | None | None |
cef9f597247657d720a773e5e571bda396a2d7e8 | cco | None | In patients with early (T1) glottic cancer, what is the role of endolaryngeal surgery (with or without laser) versus radiation therapy, in terms of survival, locoregional control, laryngeal preservation rates and voice outcomes?
# TARGET POPULATION
The target population of this guideline is adult patients with previou... | An assessment conducted in November 2021 placed Guideline 5-2 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each docu... | None | None |
93a582036a625437a37888c84aa3a47544d43930 | cco | None | This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The reco... | This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The reco... | None | None |
de26c293d2799fd9a276816e47c1b59af15a7a40 | cco | None | Anthracyclines have been established to be superior to some non-anthracycline chemotherapy regimens (Table 2 in Evidence Summary). Studies included in the EBCTCG 2012 meta-analysis (1) indicate that in general, anthracycline-based regimens are superior to non-anthracycline non-taxane regimens, provided that an optimal... | Anthracyclines have been established to be superior to some non-anthracycline chemotherapy regimens (Table 2 in Evidence Summary). Studies included in the EBCTCG 2012 meta-analysis (1) indicate that in general, anthracycline-based regimens are superior to non-anthracycline non-taxane regimens, provided that an opti... | None | None |
b914e6b71fdc75fdd9699f8d9e801d9b179b4aaa | cco | None | Evidence-based Series (EBS) 5-3 is ARCHIVED. The guidance for the organization of care has been updated; see 5-3ORG Version 2. The guidance for the clinical management of Head and Neck cancer patients is no longer current and should not be used to inform clinical decisions, but may still be useful for academic or other... | Evidence-based Series (EBS) 5-3 is ARCHIVED. The guidance for the organization of care has been updated; see 5-3ORG Version 2. The guidance for the clinical management of Head and Neck cancer patients is no longer current and should not be used to inform clinical decisions, but may still be useful for academic or other... | None | None |
21c096cb3d28108578f0eaab6504d0a6402a51ce | cco | None | Series 2-11 Version 4 REQUIRES UPDATING. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol). EBS 2-11v4 is comprised of 4 sections.# Guideline Report His... | Series 2-11 Version 4 REQUIRES UPDATING. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol). EBS 2-11v4 is comprised of 4 sections.# Guideline Report His... | None | None |
f0f29e1e11ad077264b6a7ff9a16c04df3b12fff | cco | None | To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of... | To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of... | None | None |
be361e860309fb3df832baab4b0b6d5f3620eaf6 | cco | None | # GUIDELINE OBJECTIVES
To evaluate the appropriateness of, and make recommendations on, routine testing for human papillomavirus (HPV) status in adult patients with primary, or neck nodal metastatic, squamous cell carcinoma (SCC) of the head and neck.
# TARGET POPULATION
Adult patients with squamous cell carcinomas ar... | #
Guideline Recommendations
The 2013 guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Assessment and Review for a summary of updated evidence published between 2013 and 2019, and for details on how this... | None | None |
1512e376a0bacb0aa98f7fb2fade55b89f981b0a | cco | None | # GUIDELINE OBJECTIVE
This guideline was written to provide guidance on the most appropriate follow-up strategy for patients with cervical cancer who are clinically disease-free after receiving primary treatment. This guideline is an update of a previous version, which was published in 2009. The update was initiated wh... | An assessment conducted in November 2022 placed Guideline 4-16 Version 2 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency o... | None | None |
ea2a8f7588acfbf9377a7f8a7e945f4ce166b052 | cco | None | # GUIDELINE OBJECTIVES
To make recommendations with respect to: 1. a) The use of multiparametric magnetic resonance imaging (MPMRI) in patients with an elevated risk of clinically significant prostate cancer (CSPCa) who are biopsy naïve, b) The use of MPMRI-targeted biopsy plus transrectal ultrasound systematic biopsy ... | An assessment conducted in January 2023 deferred the review of Guideline 27-2 Version 2. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document. (PEBC Assessment & Review Protocol) Guideline 27-2 Version 2... | None | None |
d052ff05f9ba60b3fba53bbd15732fbad373d31d | cco | None | # TARGET POPULATION
Adult and paediatric patients who have received an allogeneic transplant and are experiencing graft-versus-host disease.
# RECOMMENDATIONS AND JUSTIFICATION
# Extra-corporeal Photopheresis (ECP) in the Management of Graft-Versus-Host Disease (GVHD)
- ECP is an acceptable therapy for the treatment ... | # TARGET POPULATION
Adult and paediatric patients who have received an allogeneic transplant and are experiencing graft-versus-host disease.
# RECOMMENDATIONS AND JUSTIFICATION
# Extra-corporeal Photopheresis (ECP) in the Management of Graft-Versus-Host Disease (GVHD)
• ECP is an acceptable therapy for the treatment ... | None | None |
06e4a7097e28f855d23e6fcfaf246e6edbb58a45 | cco | None | # Guideline Report History
# Target Population
These recommendations apply to women with newly diagnosed stage I ovarian cancer.
- The stage of ovarian cancer is an important prognostic factor that influences survival and the choice of therapy. The quality of the surgical staging is a key determinant of treatment reco... | # Guideline Report History
# Target Population
These recommendations apply to women with newly diagnosed stage I ovarian cancer.
# Recommendations
• The stage of ovarian cancer is an important prognostic factor that influences survival and the choice of therapy. The quality of the surgical staging is a key determinan... | None | None |
e22daf935ae7d73d6102add25804ccb16fe50e40 | cco | None | # GUIDELINE OBJECTIVES
The guideline objective was to make evidence-based recommendations about APN roles (i.e., CNS, NP) for optimizing patient, provider, and health system outcomes across the cancer journey. Based on this objective, this guidance document address two specific questions:
(1) For which patient populati... | An assessment conducted in November 2022 deferred the review of Evidence-Based Series (EBS) 16-4. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol) EBS 16-4 is comp... | None | None |
d0c6fa9eb734a9aca2083d0c8e3df5271c01a595 | cco | None | Questions What is the optimal surgical management of ductal carcinoma in situ (DCIS) of the breast? Should breast irradiation be offered to women with DCIS, following breast-conserving surgery (defined as excision of the tumour with microscopically clear resection margins)? Are there patients who could be spared brea... | The PEBC is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding agencies. Copyright This evidence-based series is copyrighted by Cancer Care Ontario; the series and the illustrations herein may not be rep... | None | None |
8d51bc24821c3d5102f772a7fa61de7510b2a99c | cco | None | # INTENDED PURPOSE
This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imaging an... | # INTENDED PURPOSE
This recommendation report is primarily intended to guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imaging an... | None | None |
8c29b4ffee8337b61c376ef6336ebdc34526f667 | cco | None | GUIDELINE OBJECTIVES 1. To determine whether sentinel lymph node biopsy (SLNB) can safely and effectively identify women with node-negative, early-stage vulvar cancer and can be used as an alternative to inguinofemoral lymph node dissection (IFLD). 2. To provide guidance with respect to the appropriate techniques and p... | #
GUIDELINE OBJECTIVES 1. To determine whether sentinel lymph node biopsy (SLNB) can safely and effectively identify women with node-negative, early-stage vulvar cancer and can be used as an alternative to inguinofemoral lymph node dissection (IFLD). 2. To provide guidance with respect to the appropriate techniques an... | None | None |
44dcd45a46c5f7d2672fd9f5d467711048246afb | cco | None | # Evidence-Based Series #2-4 Version 3:
Preoperative Therapy Preoperative chemoradiotherapy (CRT) is preferred, compared to preoperative RT (standard fractionation: longer course: 45-50.4Gy in 25-28 fractions) alone, to decrease local recurrence. Preoperative CRT is preferred, compared with a postoperative approach, ... | # Evidence-Based Series #2-4 Version 3:
Section
# RECOMMENDATIONS
Preoperative Therapy Preoperative chemoradiotherapy (CRT) is preferred, compared to preoperative RT (standard fractionation: longer course: 45-50.4Gy in 25-28 fractions) alone, to decrease local recurrence. Preoperative CRT is preferred, compared wi... | None | None |
2bc7f8f2a1ffdd0595665c643fc6eac271dd2d3b | cco | None | # GUIDELINE OBJECTIVES
The objectives of the guideline are to make recommendations regarding the addition of neoadjuvant/concurrent/adjuvant chemotherapy to chemoradiotherapy in the management of locally advanced squamous cell or undifferentiated nasopharyngeal cancer (NPC) and to identify the optimal chemotherapeutic ... | This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or ... | None | None |
cfcb8ab63da1f86bf6a7b08ae858de62fa698f64 | cco | None | # Section 1:
Recommendations Summary …………………………………………… 1 Section 2:
Guideline …………………………………………………………………………… 3 Section 3: Section 4: Section 5: Guideline Methods Overview …………………………………………… 9 Evidence Review.………………………………………………………………. 12 Internal and External Review ………………………………………... 56
For information about this documen... | # Section 1:
Recommendations Summary …………………………………………… 1 Section 2:
Guideline …………………………………………………………………………… 3 Section 3: Section 4: Section 5: Guideline Methods Overview …………………………………………… 9 Evidence Review.………………………………………………………………. 12 Internal and External Review ………………………………………... 56
For information about this documen... | None | None |
0bc3ca94ead921fd7d69542177c6068426746dfb | cco | None | Lung cancers are the leading cause of cancerrelated deaths for men and women throughout the world. In the United States, approximately 224,000 new lung cancers are expected in 2016, and more than 158,000 individuals are expected to die as a result of the disease. 1 Five-year survival rates range from 67% for T1N0 disea... | Author
# INTRODUCTION
Lung cancers are the leading cause of cancerrelated deaths for men and women throughout the world. In the United States, approximately 224,000 new lung cancers are expected in 2016, and more than 158,000 individuals are expected to die as a result of the disease. 1 Five-year survival rates range ... | None | None |
8b697ad8f7efee5e3672260c94e42ad7aa0a0807 | cco | None | New evidence added to Section 1 and new data found in Section 4 Updated web publication 2012 recommendations ENDORSED Update of version 2 August 2018 NA MSLT-II trial added to Section 1 only Updated web publication Recommendation 1b updated with the data from the MSLT-II trial. For details see Appendix 3#
- What is th... | New evidence added to Section 1 and new data found in Section 4 Updated web publication 2012 recommendations ENDORSED Update of version 2 August 2018 NA MSLT-II trial added to Section 1 only Updated web publication Recommendation 1b updated with the data from the MSLT-II trial. For details see Appendix 3#
- What is th... | None | None |
6c1bf28905b56d0fb8374ba39696205288ef3032 | cco | None | October 2015 placed Evidence-based Series (EBS) 2-12 Version 2 in the EDUCATION AND INFORMATION section. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes. The PEBC has a formal and standardize process to ensure the currency of each docum... | October 2015 placed Evidence-based Series (EBS) 2-12 Version 2 in the EDUCATION AND INFORMATION section. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes. The PEBC has a formal and standardize process to ensure the currency of each docum... | None | None |
8aa8f3c2655638947aba3fd064d399f2b6272858 | cco | None | A practice guideline report on adjuvant RT following prostatectomy in patients with pT3 or margin-positive prostate cancer was originally completed by the Program in Evidence-Based Care Genitourinary Disease Site Group (PEBC GU DSG) in February 2008. The systematic review, as originally published in February 2008, can ... | These
# INTRODUCTION
A practice guideline report on adjuvant RT following prostatectomy in patients with pT3 or margin-positive prostate cancer was originally completed by the Program in Evidence-Based Care Genitourinary Disease Site Group (PEBC GU DSG) in February 2008. The systematic review, as originally published ... | None | None |
49ed880ef0445db46caa9f68a466308b07914a68 | cco | None | # Guideline Document History
# Qualifying Statement -Added to the 2017 Endorsement:
The recommendations for pathology were updated to align with the most recent CAP protocol released in February 2017 (2), based on the International Society of Urological Pathology (ISUP) consensus conferences in 2009 (3-8) and 2014 (9,... | # Guideline Document History
GUIDELINE
# Qualifying Statement -Added to the 2017 Endorsement:
The recommendations for pathology were updated to align with the most recent CAP protocol released in February 2017 (2), based on the International Society of Urological Pathology (ISUP) consensus conferences in 2009 (3-8) an... | None | None |
a7dc89781112ae995210e98beb24314cc644fb44 | cco | None | PDT is a local treatment. It utilizes the local, selective, cytotoxic reaction produced by photosensitizers when activated by red nonthermal laser light of a specific wavelength. This cytotoxic effect is achieved through the generation of free radicals, the production of singlet oxygen via energy transfer from light to... | These
# INTRODUCTION
PDT is a local treatment. It utilizes the local, selective, cytotoxic reaction produced by photosensitizers when activated by red nonthermal laser light of a specific wavelength. This cytotoxic effect is achieved through the generation of free radicals, the production of singlet oxygen via energy ... | None | None |
a6749df174b95cd4c95728ca3e94287a550cef0d | cco | None | What is the optimal post-orchidectomy management strategy for stage I testicular seminoma? Outcomes of interest include cancer-specific survival, long-term toxicity (including second malignancy), and quality of life.
# TARGET POPULATION
Adult patients with stage I testicular seminoma.
# RECOMMENDATIONS AND KEY EVIDEN... | # QUESTION
What is the optimal post-orchidectomy management strategy for stage I testicular seminoma? Outcomes of interest include cancer-specific survival, long-term toxicity (including second malignancy), and quality of life.
# TARGET POPULATION
Adult patients with stage I testicular seminoma.
# RECOMMENDATIONS AND... | None | None |
214357bc91fea9508a8b58a4c2ca3a986144c867 | cco | None | Guideline Questions a) What is the optimal chemotherapy for patients with multiple myeloma? b) In terms of survival, is peripheral blood stem cell or autologous bone marrow transplantation better than conventional chemotherapy? c) What is the relative efficacy of autologous and allogeneic transplantation? d) What speci... | Guideline Questions a) What is the optimal chemotherapy for patients with multiple myeloma? b) In terms of survival, is peripheral blood stem cell or autologous bone marrow transplantation better than conventional chemotherapy? c) What is the relative efficacy of autologous and allogeneic transplantation? d) What speci... | None | None |
02a75f43fbb622bf4313e9292423cfbe30e0c46c | cco | None | # A. INTRODUCTION Guideline Objective
The objective of this guideline is to provide the basis for a quality assurance program for all colonoscopy procedures done in the province of Ontario, including those conducted as part of the fecal occult blood test (FOBT)-based colorectal cancer (CRC) screening program. This guid... | # A. INTRODUCTION Guideline Objective
The objective of this guideline is to provide the basis for a quality assurance program for all colonoscopy procedures done in the province of Ontario, including those conducted as part of the fecal occult blood test (FOBT)-based colorectal cancer (CRC) screening program. This guid... | None | None |
dff6a9c83874c1c5146da4502ed42e530de41f12 | cco | None | Questions JUDGEMENTS The GDG considered this topic a low priority for health economic analysis.
The Working Group members agreed that the feasibility of PCI for this population has been well established.
# Appendix 1: Affiliations and Conflict of Interest Declarations
In accordance with the PEBC Conflict of Interest P... | Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinic... | None | None |
a2d7e432bbbc21cf4f34e771f0de3a0258e4dfec | cco | None | For information about the PEBC and the most current version of all reports, please visit the CCO website at / or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca
# Bone Health and Bone-Targeted Therapies for Prostate Cancer
Recommendations This is a quick referenc... | Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinic... | None | None |
68702a0a1bf98af60908294fd393240bfeef7137 | cco | None | # RECOMMENDATIONS (The recommendations were slightly modified with respect to risk category 5 during the 2017 ENDORSEMENT)
MRI in addition to mammography is recommended for women in target population risk categories 1, 2, 3, and 5 above. The evidence is insufficient to recommend MRI screening for patients in risk categ... | # RECOMMENDATIONS (The recommendations were slightly modified with respect to risk category 5 during the 2017 ENDORSEMENT)
MRI in addition to mammography is recommended for women in target population risk categories 1, 2, 3, and 5 above. The evidence is insufficient to recommend MRI screening for patients in risk categ... | None | None |
2871e44cbe0808ce98543c7741d28d544646d95b | cco | None | December 2018 placed Evidence-Based Series (EBS) 26-3 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document (PE... | December 2018 placed Evidence-Based Series (EBS) 26-3 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document (PE... | None | None |
565ac1a533ff3f66d0485f909a8cb4aa96b2ed90 | cco | None | # GUIDELINE OBJECTIVES
This guideline aims:
-To describe the role of active surveillance (AS) as a management strategy for patients with localized prostate cancer. -To identify patients with prostate cancer that would most benefit from AS.
-To develop an evidence-based protocol for AS in localized prostate cancer and t... | # GUIDELINE OBJECTIVES
This guideline aims:
-To describe the role of active surveillance (AS) as a management strategy for patients with localized prostate cancer. -To identify patients with prostate cancer that would most benefit from AS.
-To develop an evidence-based protocol for AS in localized prostate cancer and t... | None | None |
05898a8d8f713aa6b3692b84eb0df7a6f7211ff5 | cco | None | For information about this document, please contact Dr. Eric Winquist, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca
For information about the PEBC and the most current version of all reports, please visit the CCO website at / or contact the PEBC offi... | #
For information about this document, please contact Dr. Eric Winquist, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca
For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.o... | None | None |
5af930a1cf161ffa36d740d22021619c7eaa6409 | cco | None | Questions 1. What treatment provides the optimum disease control and survival in older patients (at least 60 years of age) with newly diagnosed, advanced-stage, aggressive histology lymphoma? 2. What are the toxicities associated with these treatments? 3. What are the roles of granulocyte-colony stimulating factor or g... | Questions 1. What treatment provides the optimum disease control and survival in older patients (at least 60 years of age) with newly diagnosed, advanced-stage, aggressive histology lymphoma? 2. What are the toxicities associated with these treatments? 3. What are the roles of granulocyte-colony stimulating factor or g... | None | None |
bc922ee0adc578f1f7f44626319486ffad189290 | cco | None | To provide an updated guideline on the use of rituximab in lymphoma and chronic lymphocytic leukemia (CLL).#
For information about this document, please contact Dr. Tom Kouroukis or Dr. Matthew Cheung through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca:
For information abo... | To provide an updated guideline on the use of rituximab in lymphoma and chronic lymphocytic leukemia (CLL).#
For information about this document, please contact Dr. Tom Kouroukis or Dr. Matthew Cheung through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca:
For information abo... | None | None |
ecfb7ee9fd0e75064a2f2c2ebb62193850375ca6 | cco | None | Version 2 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document.# Guideline Report History
# Target Population... | Version 2 IN REVIEW. This means that it is undergoing a review for currency and relevance. It is still appropriate for this document to be available while this updating process unfolds. The PEBC has a formal and standardized process to ensure the currency of each document.# Guideline Report History
# Target Population... | None | None |
f94f984e338d56e3b9ccbcda0f388de7fec3cf66 | cco | None | The 2014 guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Assessment and Review for a summary of updated evidence published between 2013 and 2022, and for details on how this guideline was ENDORSED.
What... | #
The 2014 guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Assessment and Review for a summary of updated evidence published between 2013 and 2022, and for details on how this guideline was ENDORSED.
... | None | None |
138cbf85437d72e5c66b6e0f4955b9ba1654786d | cco | None | The Ontario Cervical Screening Program (OCSP) is currently being relaunched to incorporate an organized call and recall component. This relaunch has necessitated a review of evidence related to the research questions listed above and an update of the relevant portions of the Program in Evidence-based Care (PEBC) May 20... | An assessment conducted in April 2016 placed Evidence-based Series (EBS) 15-9 IN REVIEW. This means that it is undergoing a review for currency and relevance. The PEBC has determined that it is still appropriate for this document to continue to be available while this updating process unfolds. The PEBC has a formal and... | None | None |
67f77727b81d260821298340fee029dfa0c19881 | cco | None | 2b. In female patients with locally advanced breast cancer does locoregional irradiation result in higher survival and lower recurrence rates compared with breast/chest wall irradiation alone? 2c. In female patients with locally advanced breast cancer and pathologically complete response to neoadjuvant therapy is radio... | #
2b. In female patients with locally advanced breast cancer does locoregional irradiation result in higher survival and lower recurrence rates compared with breast/chest wall irradiation alone? 2c. In female patients with locally advanced breast cancer and pathologically complete response to neoadjuvant therapy is ra... | None | None |
caa53d1af1fdf745c71870f383c13c96d6c8d112 | cco | None | Recommendation Report SCT-6: Section 1
# Stem Cell Transplantation in the Treatment of Acute
Lymphoblastic Leukemia: Recommendations OBJECTIVES 1. To establish the indications for allogeneic stem cell transplantation (allo-SCT) in the management of acute lymphoblastic leukemia (ALL) in adults 2. To identify the role o... | Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario... | None | None |
13d0f084bbe6051daa2dd1e53903505526115f7c | cco | None | # GUIDELINE OBJECTIVES
- To provide clinical guidance with respect to suitability for breast reconstruction, timing of reconstruction, and optimal reconstruction techniques. - To make recommendations that will inform decisions at the policy and administration level aimed at improving the quality of life of women with b... | Increased risk for Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) exists with the use of textured breast implants. See the Health Canada recalls and alerts webpage for more information https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70045a-eng.php An assessment conducted in Janua... | None | None |
34cea62983d0bee2013d8f35a9dda2de373e9ee5 | cco | None | # INTENDED PURPOSE
To summarize the available evidence regarding provider tools for ACP or GoCD.
# INTENDED USERS
Healthcare providers who engage in ACP or GoCD with their patients or should engage in ACP or GoCD with their patients and administrators who wish to provide ACP or GoCD training to providers within their ... | Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario... | None | None |
6f06f30a38e8b3326960e5203cd2a48226aaebf0 | cco | None | # GUIDELINE OBJECTIVES
To recommend systemic therapy options for women with recurrent epithelial ovarian cancer including fallopian tube and primary peritoneal cancers.
# TARGET POPULATION
The target population comprises women with recurrent epithelial ovarian cancer who have previously received platinum-based chemoth... | and the Gynecologic Cancer Disease Site Group An assessment conducted in November 2022 deferred the review of Guideline 4-3 Version 4. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessmen... | None | None |
4c8c8270ece395b2f9e878cda469666e547b3eba | cco | None | Guideline Questions 1. What are the chemotherapeutic and hormonal therapy options for women with advanced or recurrent endometrial cancer (excluding sarcomas and squamous cell carcinomas)? 2. What are the chemotherapeutic options for women with advanced or recurrent uterine papillary serous carcinoma?
# Target Populat... | # SUMMARY
Guideline Questions 1. What are the chemotherapeutic and hormonal therapy options for women with advanced or recurrent endometrial cancer (excluding sarcomas and squamous cell carcinomas)? 2. What are the chemotherapeutic options for women with advanced or recurrent uterine papillary serous carcinoma?
# Targ... | None | None |
b126b8639e28a38c3f8e1291b8c420ba28ccbb06 | cco | None | # GUIDELINE OBJECTIVES
To provide guidance on the optimal systemic therapies for the treatment of advanced gastric and gastro-esophageal junction (GEJ) carcinoma. Optimal systemic therapies were defined as those that provided improved overall survival and improved quality of life.
# TARGET POPULATION
Adult patients (a... | Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinic... | None | None |
9b123907b87bdbf96d37534b03913cc29f3d6da1 | cdc | None | The purpose of the memorandum is to exchange information and expertise in the area of occupational safety and health. One product of this agreement is the development of documents to provide the scientific basis for establishing recommended occupational exposure limits. These limits will be developed separately by the ... | The purpose of the memorandum is to exchange information and expertise in the area of occupational safety and health. One product of this agreement is the development of documents to provide the scientific basis for establishing recommended occupational exposure limits. These limits will be developed separately by the ... | None | None |
8cd99385e65cdabd7c31e3781bee417d1b323cc1 | cdc | None | # Table of Contents
List of Tables, Figures , and Boxes
# Summary
Preexposure Prophylaxis for HIV Prevention in the United States -2013: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection... | # Table of Contents
List of Tables, Figures , and Boxes
# Summary
Preexposure Prophylaxis for HIV Prevention in the United States -2013: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection... | None | None |
e2fd70c208f35255409a4062bbf04740830c4cd0 | cdc | None | This report is being published as a courtesy to both the National Association of State Public Health Veterinarians, Inc., and to the MMWR readership. Its publication does not imply endorsement by CDC.#
Copies also can be accessed at the CDC website at and the American Veterinary Medical Association website at .
# Com... | This report is being published as a courtesy to both the National Association of State Public Health Veterinarians, Inc., and to the MMWR readership. Its publication does not imply endorsement by CDC.#
Copies also can be accessed at the CDC website at <http://www.cdc.gov/ncidod> and the American Veterinary Medical Ass... | None | None |
1e634bfa4a7adce3e3f5037b78378c7b41a6d5c3 | cdc | None | Chairman/Criteria Group NIOH In an Italian factory for production of n-butyl phthalate, isobutyl phthalate, and DEHP, G ilioli et al (36) measured to tal phthalate exposure 3 concentrations between 1 and 60 mg/m with an average air concentration 3 (not stated whether arithmetic or geometric) around 5 mg/m . Nielsen et ... | Chairman/Criteria Group NIOH In an Italian factory for production of n-butyl phthalate, isobutyl phthalate, and DEHP, G ilioli et al (36) measured to tal phthalate exposure 3 concentrations between 1 and 60 mg/m with an average air concentration 3 (not stated whether arithmetic or geometric) around 5 mg/m . Nielsen et ... | None | None |
6df275fac6fb02413f202f9fe4917a5233556819 | cdc | None | In 2010, the Advisory Committee on Immunization Practices (ACIP) first recommended annual influenza vaccination for all persons aged ≥6 months in the United States (1). Annual influenza vaccination of all persons aged ≥6 months continues to be recommended. This document 1) describes influenza vaccine virus strains incl... | #
In 2010, the Advisory Committee on Immunization Practices (ACIP) first recommended annual influenza vaccination for all persons aged ≥6 months in the United States (1). Annual influenza vaccination of all persons aged ≥6 months continues to be recommended. This document 1) describes influenza vaccine virus strains i... | None | None |
e69c9fcd34da13e6c948998ac570276a92b3b5bf | cdc | None | # CRITERIA DOCUMENT: RECOMMENDATIONS FOR AN OCCUPATIONAL EXPOSURE STANDARD FOR INORGANIC LEAD
recommends that employee exposure to inorganic lead in the workplace be controlled by adherence to the following sections. The standard is designed to protect the health and safety of workers for an 8-hour day, 40-hour week ov... | # CRITERIA DOCUMENT: RECOMMENDATIONS FOR AN OCCUPATIONAL EXPOSURE STANDARD FOR INORGANIC LEAD
recommends that employee exposure to inorganic lead in the workplace be controlled by adherence to the following sections. The standard is designed to protect the health and safety of workers for an 8-hour day, 40-hour week ov... | None | None |
c967d2e72d0f4b341d0a71f00b751aa6dc027003 | cdc | None | This manual introduces the reader to the principles and practical tools of crisis and emergency risk communication (CERC). Principles in this manual adapt (1) writings of classical rhetoricians; (2) a wealth of modern crisis, issues management, communication theory, and psychological theory; and (3) lessons learned fro... | This manual introduces the reader to the principles and practical tools of crisis and emergency risk communication (CERC). Principles in this manual adapt (1) writings of classical rhetoricians; (2) a wealth of modern crisis, issues management, communication theory, and psychological theory; and (3) lessons learned fro... | None | None |
e2cb194bc47c7ab1919dae7545c59fea1fc9340a | cdc | None | depar depar depar depar department of health and human ser tment of health and human ser tment of health and human ser tment of health and human ser tment of health and human services vices vices vices vices#
acute renal failure, acute respiratory distress syndrome, and disseminated intravascular coagulation. He requir... | depar depar depar depar department of health and human ser tment of health and human ser tment of health and human ser tment of health and human ser tment of health and human services vices vices vices vices#
acute renal failure, acute respiratory distress syndrome, and disseminated intravascular coagulation. He requi... | None | None |
b0fb2c2654cff75ee89635f8f3a567b6d3598ec8 | cdc | None | # I. RECOMMENDATIONS FOR A STANDARD FOR WORK IN HOT ENVIRONMENTS
The National Institute for Occupational Safety and Health (NIOSH) recommends that employee exposure to heat in the workplace be controlled by requiring compliance with the work practice standard set forth in the following sections. Adherence to the precau... | # I. RECOMMENDATIONS FOR A STANDARD FOR WORK IN HOT ENVIRONMENTS
The National Institute for Occupational Safety and Health (NIOSH) recommends that employee exposure to heat in the workplace be controlled by requiring compliance with the work practice standard set forth in the following sections. Adherence to the precau... | None | None |
a04988834597e9ed31e25c40fbd8f6ce7917d4b1 | cdc | None | Scopolamine Poisoning -Continued Heroin is mixed ("cut") frequently with other substances primarily to increase its weight for retail sale (e.g., mannitol and starch) and to add pharmacologic effects (e.g., dextromethorphan and lidocaine). During 1995 and 1996, health departments and poison-control centers in New York ... | Scopolamine Poisoning -Continued Heroin is mixed ("cut") frequently with other substances primarily to increase its weight for retail sale (e.g., mannitol and starch) and to add pharmacologic effects (e.g., dextromethorphan and lidocaine). During 1995 and 1996, health departments and poison-control centers in New York ... | None | None |
926d07600e3135c49adf06dcb1d1893c4ff3816d | cdc | None | Routine vaccination of children is an effective way to reduce hepatitis A incidence in the United States. Since licensure of hepatitis A vaccine during 1995-1996, the hepatitis A childhood immunization strategy has been implemented incrementally, starting with the recommendation of the Advisory Committee on Immunizatio... | Routine vaccination of children is an effective way to reduce hepatitis A incidence in the United States. Since licensure of hepatitis A vaccine during 1995-1996, the hepatitis A childhood immunization strategy has been implemented incrementally, starting with the recommendation of the Advisory Committee on Immunizatio... | None | None |
67bb54a24ecaef2340b2541520a823c4684e3622 | cdc | None | As the nation's prevention agency, CDC strives to accomplish its vision of "Healthy People in a Healthy World...Through Prevention." For women, this involves working to better understand the health issues that have an adverse impact on women, disproportionately affect women, occur only in women, or have an impact on in... | As the nation's prevention agency, CDC strives to accomplish its vision of "Healthy People in a Healthy World...Through Prevention." For women, this involves working to better understand the health issues that have an adverse impact on women, disproportionately affect women, occur only in women, or have an impact on in... | None | None |
9694b3bf518b96437fd2b3ea2a3d88b0c53d6afd | cdc | None | Healthy eating patterns in childhood and adolescence promote optimal childhood health, growth, and intellectual development; prevent immediate health problems, such as iron deficiency anemia, obesity, eating disorders, and dental caries; and may prevent long-term health problems, such as coronary heart disease, cancer,... | Healthy eating patterns in childhood and adolescence promote optimal childhood health, growth, and intellectual development; prevent immediate health problems, such as iron deficiency anemia, obesity, eating disorders, and dental caries; and may prevent long-term health problems, such as coronary heart disease, cancer,... | None | None |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.